TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years of older~* Angiographically confirmed multivessel CAD \[critical (\>70%) lesions in at least two major epicardial vessels and in at least two separate coronary artery territories (LAD, LCX, RCA)\] and amenable to either PCI or CABG.~* Indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischemia~* Geographically accessible and willing to come in for required study visits~* Signed informed consent.~Exclusion Criteria:~* Severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema) at the time of enrollment.~* Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stent).~* In-stent restenosis of a target vessel~* Prior CABG surgery~* Prior PCI with stent implantation within 1 year~* Two or more chronic total occlusions in major coronary territories~* Acute ST-elevation MI(Q-wave) within 72 hours prior to enrollment requiring revascularization~* Abnormal creatine kinase (CK \> 2x normal) and/or abnormal CK-MB levels and/or elevated Troponin levels at time of randomization~* Previous stroke within 6 months or patients with stroke at more than 6 months with significant residual neurologic involvement, as reflected in a Rankin Score \> 1~* Dementia with a Mini Mental Status Examination (MMSE) score of ≤ 20~* Extra-cardiac illness that is expected to limit survival to less than 2 years; e.g. oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or significant hepatic failure, severe renal disease.~* Prior history of significant bleeding (within the previous 6 months) that might be expected to occur during CABG or PCI/DES related anticoagulation.~* Contraindication either CABG or PCI/DES because of a coexisting clinical condition~* Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis~* Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine~* Suspected pregnancy. A pregnancy test (urine or serum) will be administered prerandomization to all women not clearly menopausal~* Concurrent enrollment in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- everolimus-eluting stent (Type: EXPERIMENTAL): everolimus-eluting stent
- coronary artery bypass graft surgery (Type: ACTIVE_COMPARATOR): coronary artery bypass graft surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ADPKD patients with normal renal function,~* Normotensive ADPKD patients~Exclusion Criteria:~* Patients with impaired kidney function,~* Atherosclerotic disorders,~* Diagnosis of hypertension, gout, diabetes,~* Using of insulin, thiazide, allopurinol or uricosuric drugs

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- polycystic kidney ,no hypertension (Type: None): The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* female patients with unilateral and bloody nipple discharge OR unilateral and clear nipple discharge~* clinical decision to have contrast enhanced MRI~Exclusion Criteria:~* male gender~* non-English speakers~* age \< 21 years~* lack of capacity to give legally effective consent

- Gender: FEMALE
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MRI (Type: OTHER): Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age 18 years or older~* Documented metastatic adenocarcinoma of the prostate~* Under active medical oncology care~* ECOG performance status 0 - 3, inclusive~* Able to understand and provide written informed consent~* Able to tolerate the physical requirements of two PET/CT scans including lying for up to 30 minutes~* Progressive disease on any of: bone scan, CT, MRI or serum PSA as judged by the investigator~* Serum prostate specific antigen ≥ 1 ng/ml at baseline or CT/MRI soft-tissue measurable disease as per RECIST v1.1~* Failed, failing, refused, no access to or not eligible for any approved prostate cancer therapies including but not limited to: ADT, NAAD (e.g., abiraterone, enzalutamide, darolutamide or apalutamide), docetaxel, cabazitaxel, radium-223 and oligometastatic RTX~* Life expectancy of at least 3 months as judged by the investigator~Exclusion Criteria:~* Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)~* Exceeding the weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (approximately 70 cm diameter)~* Unmanageable claustrophobia~* Prior failure of PSMA RLT~* Prior hemi-body irradiation~* Impaired organ function as evidenced by any of the following laboratory values:~  * Absolute neutrophil count \< 1.5 x109/L~ * Platelet count \< 75 x109/L~ * Hemoglobin \< 85 g/L~ * Albumin \< 2.5 g/dL (25 g/L)~ * Total bilirubin \> 2 x ULN (unless in instances of Gilbert's disease)~ * AST or ALT \> 2.5 x ULN (or \> 5.0 x ULN in the presence of liver metastases)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 131I-PSMA-1095 Radioligand Therapy (RLT) (Type: EXPERIMENTAL): Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Knowledge and Interpersonal Skills to Develop Exemplary Relationships

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provides assistance to someone over the age of 60 with an illness or a disability (care recipient) who requires personal assistance from another person (e.g., bathing, preparing meals). (Assistance provided with at least 1 activity of daily living and/or at least 2 instrumental activities of daily living.)~* Person receiving care from the study participant has a cognitive impairment. This does not have to be diagnosed.~* Participant provides at least 8 hours of assistance to the care recipient per week~* Participant does not intend to place the care recipient in a skilled nursing facility or assisted living facility within 3 months of consenting into the study~Exclusion Criteria:~* Does not read and speak English~* Cannot access a computer and internet (needed to complete lessons)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- KINDER Participant (Type: EXPERIMENTAL): The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hemi-diaphragmatic Paresis After Erector Spinae Plane Block

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 - 85 years~* American Society of Anesthesiology (ASA) I-III~* elective carotid endarterectomy~Exclusion Criteria:~* patient's refusal~* under 18 years of age or over 65 years of age~* ASA IV and above~* known allergy to local anaesthetic drugs~* the block cannot be applied due to bleeding disorders or localized skin infection at the injection site~* history of neurological and/or neuromucular disease~* history of severe bronchopulmonary disease~* a moderate to severe decrease in preoperative pulmonary function, or abnormality in preoperative chest radiography data (pleural effusion, pneumothorax, or hemidiaphragm elevation)~* emergency surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ESP block group (Type: None): Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key inclusion criteria:~* Female subject~* 18 years of age or older~Cohort A specific inclusion criteria:~• Diagnosed with a pelvic mass~Cohort B specific inclusion criteria:~* Diagnosed with a pelvic mass~* Undergoing genetic testing through our commercial offering~Cohort C specific inclusion criteria:~• Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.~Exclusion Criteria:~* n/a

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COHORT A (Type: None): Women with a pelvic mass, symptomatic or asymptomatic.
- COHORT B (Type: None): Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
- COHORT C (Type: None): Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female age 18-60.~* Histologically confirmed early stage invasive ductal or lobular carcinoma of a single breast (T1N0M0-T2N0M0) or DCIS/LCIS (TisNxMx or TisN0M0) of a single breast.~* Deemed fit to undergo adjuvant radiotherapy to their breast by their supervising radiation oncologist.~* Able to provide written informed consent.~* Must be willing to be contacted by e-mail and have a valid e-mail account to complete follow up self-reported body image scale questionnaires.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~* Intact skin at site of standard radiotherapy tattoos. Must have access to a computer and be able and willing to comply with requirements of the protocol.~Exclusion Criteria:~* History of any prior radiotherapy courses to the chest or abdomen.~* Metastatic disease.~* Node positive breast cancer.~* Bilateral breast cancer or bilateral DCIS/LCIS.~* Deep-inspiration breath hold radiotherapy technique.~* Unable or unwilling to comply with the requirements of the protocol as assessed by the study investigator or coordinator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 - UV ink (Type: EXPERIMENTAL): Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
- Arm 2 - Black ink (Type: NO_INTERVENTION): Radiotherapy tattoos will be applied using standard black ink.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged ≥ 18~* Subjects diagnosed of functioning or non-functioning PanNET, G1/ G2 (Ki67≤10%) unresectable locally advanced tumour or metastatic disease, who have been treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months~* Subject not progressive at inclusion study visit according to investigator assessment, and using as a reference lanreotide initiation~* Subject with Eastern Cooperative Oncology Group (ECOG) ≤2~Exclusion Criteria:~* Subject who is participating in an interventional study~* Pregnant or breast-feeding women~* Subject who has received any previous therapy for PanNET (such as octreotide LAR, Molecular Targeted Therapy (MTT), Peptide receptor radionuclide therapy (PRRT), chemotherapy, etc.) except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized in haemato-oncology ward starting filgrastim for the treatment of chemotherapy-induced neutropenia.~* Will include patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), aggressive lymphoma or multiple myeloma.~* Will include both patients with or without a documented infection at the time of CSF initiation. Initiation of filgrastim treatment will follow the 2006 ASCO guidelines (departmental routines).~Exclusion Criteria:~* The investigators will exclude patients receiving CSFs for their primary disease (e.g. aplastic anemia, myelodysplastic syndromes) and pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- IV filgrastim (Type: EXPERIMENTAL): as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg) in bolus IV injection, as per manufacturer's recommendations.
- SC filgrastim (Type: ACTIVE_COMPARATOR): given as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Definite IE, according to modified ESC 2015 criteria, caused by gram-positive cocci (staphylococci, streptococci and enterococci), including native, prosthetic valve IE and cardiac device-related IE.~* 18 years old or older.~* Patients treated for at least 10 days of appropriate parenteral antibiotic therapy overall (according to guidelines and microbiology sensitivity testing), and at least 7 days of parenteral antibiotic therapy after valve surgery when indicated.~* Absence of fever, microbiological or analytical findings suggesting persistent infection at randomization.~* Absence of locally uncontrolled infection signs (abscess, pseudoaneurysm, fistula, enlarging vegetation) at randomization, confirmed by recent transesophageal echocardiography (performed within 48 h of randomization).~* Women of childbearing potential who will agree to the use of effective contraceptive methods while on antibiotic treatment.~Exclusion Criteria:~* Patients who have received appropriate parenteral antibiotic therapy for infective endocarditis for more than 12 days.~* Patients not suitable to be discharged after 10 days of conventional treatment, due to clinical reasons (sequels of stroke that prevent discharge, progressive renal failure, hepatic failure).~* Patients receiving chemotherapy or immunosuppressive therapy.~* Pregnant or breastfeeding women.~* Need of prolonged antibiotic therapy due to spondylodiscitis or other septic complication.~* Absence of patient's ability or commitment to continue follow-up after being discharged from hospital.~* Inability to give informed consent to participation.~* Cognitive impairment or lack of language skills needed to complete the questionnaires.~* Patients who meet urgent cardiac surgery ESC criteria but are considered inoperable due to high surgical risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short course (Type: EXPERIMENTAL): Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
- Standard course (Type: ACTIVE_COMPARATOR): Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must voluntarily sign and date an informed consent before the initiation of any study procedures~* Patients must have non-metastatic, inoperable, Stage IIIA or IIIB histologically or cytologically documented NSCLC without evidence of malignant pleural effusion~* Patients must not have received any prior systemic chemotherapy, thoracic radiotherapy or surgical resection for treatment of NSCLC~* Patients must have at least one site of unidirectionally measurable disease~* Patients must be ≥ 3 weeks from a formal exploratory thoracotomy~* Patients must have a Radiation Oncology and Medical Oncology consult and approval prior to study entry~* Patients must be ≥ 18 years of age~* Women of childbearing potential must have a negative baseline serum pregnancy within 7 days prior to Week 1, Day 1 and must not be breast feeding.~* Women of childbearing potential and men with a sexual partner of child bearing potential must use an effective method of contraception beginning prior to study entry, for the duration of the study participation and for a minimum of 3 months after the last dose of chemotherapy.~* Patients must have adequate hepatic, renal, lung and bone marrow function as defined below:~  * Absolute neutrophil count (ANC) \> 1,500/mm3~ * Hemoglobin \> 9.0 gm/dL~ * Creatinine \< 1.5~ * Platelets \> 100,000/mm3~ * Total bilirubin within normal limits (WNL)~ * AST or ALT and Alkaline Phosphatase must be within the range allowing for eligibility, as per chart on page 10 of the protocol.~* Calculated CrCl \> 50 ml/min (via Cockroft-Gault formula).~* Forced expiratory volume in 1 second (FEV 1) \> 800 ml~Exclusion Criteria:~* Known hypersensitivity to drugs formulated with polysorbate 80~* Peripheral neuropathy Grade ≥ 2.~* Wet stage IIIB (documented malignant pleural effusion) or stage IV NSCLC~* Previous chemotherapy or radiation therapy~* Any concomitant malignancy, brain metastasis or uncontrolled, clinically significant medical or psychiatric disorder~* Pregnant or nursing women~* A greater than or equal to 10% weight loss over the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy